Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 26.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $41.865 million which beat the analyst consensus estimate of $37.326 million by 12.16 percent. This is a 633.06 percent increase over sales of $5.711 million the same period last year.